Soleno Therapeutics Inc. (SLNO)
43.71
1.17 (2.75%)
At close: Jan 15, 2025, 9:41 AM
Company Description
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases.
Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program.
The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017.
Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.
Soleno Therapeutics Inc.
| Country | United States |
| IPO Date | Nov 13, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 33 |
| CEO | Dr. Anish Bhatnagar M.D. |
Contact Details
Address: 203 Redwood Shores Parkway Redwood City, California United States | |
| Website | https://soleno.life |
Stock Details
| Ticker Symbol | SLNO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001484565 |
| CUSIP Number | 834203200 |
| ISIN Number | US8342033094 |
| Employer ID | 77-0523891 |
| SIC Code | 3845 |
Key Executives
| Name | Position |
|---|---|
| Dr. Anish Bhatnagar M.D. | President, Chief Executive Officer, Chief Operating Officer & Director |
| James H. MacKaness | Chief Financial Officer |
| Dr. Michael Huang M.D. | Senior Vice President of Clinical Development |
| Dr. Neil M. Cowen M.B.A., Ph.D. | Senior Vice President of Drug Development |
| Dr. Raymond W. Urbanski M.D., Ph.D. | Chief Development Officer |
| Jesse Schumaker | General Counsel |
| Kristen Yen M.S. | Senior Vice President of Clinical Operations |
| Lauren Budesheim | Vice President of People |
| Meredith Manning M.B.A. | Chief Commercial Officer |
| Patricia C. Hirano M.P.H. | Senior Vice President of Regulatory Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 06, 2025 | 4 | Filing |
| Jan 06, 2025 | 4 | Filing |
| Jan 06, 2025 | 4 | Filing |
| Jan 06, 2025 | 4 | Filing |
| Dec 17, 2024 | 8-K | Current Report |
| Nov 26, 2024 | 8-K | Current Report |
| Nov 19, 2024 | SC 13D/A | [Amend] Filing |
| Nov 14, 2024 | SCHEDULE 13G/A | [Amend] Filing |
| Nov 14, 2024 | SC 13D/A | [Amend] Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |